A NEW one-dose vaccine against
typhoid, developed by K P Klugman
of South Africa, has recently been
licensed and introduced in India.
The vaccine does not cause the
swelling and fever associated with
other typhoid vaccines and its effect
lasts for 3 years, claims Klugman.
Tests undertaken in Nepal reveal
that 17 months after a shot of the
new vaccine, only about 4 per cent of
the recipients developed the disease.
Says Klugman, "No vaccine offers
100 per cent protection."
In the absence of treatment, the
death rate from typhoid can be as
high as 30 per cent. Conventional
vaccines that protect against the disease are given in three doses. In
India, the vaccine will be marketed
by Cadilla at Rs 450 a dose.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
.png)
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.